ID   PLMN_HUMAN              Reviewed;         810 AA.
AC   P00747; Q15146; Q5TEH4; Q6PA00;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 2.
DT   10-MAY-2017, entry version 220.
DE   RecName: Full=Plasminogen;
DE            EC=3.4.21.7;
DE   Contains:
DE     RecName: Full=Plasmin heavy chain A;
DE   Contains:
DE     RecName: Full=Activation peptide;
DE   Contains:
DE     RecName: Full=Angiostatin;
DE   Contains:
DE     RecName: Full=Plasmin heavy chain A, short form;
DE   Contains:
DE     RecName: Full=Plasmin light chain B;
DE   Flags: Precursor;
GN   Name=PLG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASN-472.
RX   PubMed=2318848;
RA   Petersen T.E., Martzen M.R., Ichinose A., Davie E.W.;
RT   "Characterization of the gene for human plasminogen, a key proenzyme
RT   in the fibrinolytic system.";
RL   J. Biol. Chem. 265:6104-6111(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3030813; DOI=10.1016/0014-5793(87)81501-6;
RA   Forsgren M., Raden B., Israelsson M., Larsson K., Heden L.-O.;
RT   "Molecular cloning and characterization of a full-length cDNA clone
RT   for human plasminogen.";
RL   FEBS Lett. 213:254-260(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RA   Browne M.J., Chapman C.G., Dodd I., Carey J.E., Lawrence G.M.P.,
RA   Mitchell D., Robinson J.H.;
RT   "Expression of recombinant human plasminogen and aglycoplasminogen in
RT   HeLa cells.";
RL   Submitted (OCT-1991) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYS-57; GLN-133;
RP   HIS-261; TRP-408; ASN-472; VAL-494 AND TRP-523.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-676.
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 20-810, AND VARIANT ASN-472.
RA   Sottrup-Jensen L., Petersen T.E., Magnusson S.;
RL   Submitted (JUL-1977) to the PIR data bank.
RN   [8]
RP   PROTEIN SEQUENCE OF 20-100.
RX   PubMed=122932; DOI=10.1111/j.1432-1033.1975.tb09887.x;
RA   Wiman B., Wallen P.;
RT   "Structural relationship between 'glutamic acid' and 'lysine' forms of
RT   human plasminogen and their interaction with the NH2-terminal
RT   activation peptide as studied by affinity chromatography.";
RL   Eur. J. Biochem. 50:489-494(1975).
RN   [9]
RP   PROTEIN SEQUENCE OF 95-580; 581-626; 657-700 AND 732-810, AND VARIANT
RP   ASN-472.
RA   Sottrup-Jensen L., Claeys H., Zajdel M., Petersen T.E., Magnusson S.;
RT   "The primary structure of human plasminogen.";
RL   (In) Davidson J.F., Rowan R.M., Samama M.M., Desnoyers P.C. (eds.);
RL   Progress in chemical fibrinolysis and thrombolysis, pp.3:191-209,
RL   Raven Press, New York (1978).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 292-810.
RX   PubMed=6148961; DOI=10.1021/bi00313a035;
RA   Malinowski D.P., Sadler J.E., Davie E.W.;
RT   "Characterization of a complementary deoxyribonucleic acid coding for
RT   human and bovine plasminogen.";
RL   Biochemistry 23:4243-4250(1984).
RN   [11]
RP   PROTEIN SEQUENCE OF 483-604.
RX   PubMed=126863; DOI=10.1111/j.1432-1033.1975.tb02403.x;
RA   Wiman B., Wallen P.;
RT   "Amino-acid sequence of the cyanogen-bromide fragment from human
RT   plasminogen that forms the linkage between the plasmin chains.";
RL   Eur. J. Biochem. 58:539-547(1975).
RN   [12]
RP   PROTEIN SEQUENCE OF 581-810.
RX   PubMed=142009; DOI=10.1111/j.1432-1033.1977.tb11578.x;
RA   Wiman B.;
RT   "Primary structure of the B-chain of human plasmin.";
RL   Eur. J. Biochem. 76:129-137(1977).
RN   [13]
RP   ACTIVE SITE.
RX   PubMed=4694729;
RA   Robbins K.C., Bernabe P., Arzadon L., Summaria L.;
RT   "The primary structure of human plasminogen. II. The histidine loop of
RT   human plasmin: light (B) chain active center histidine sequence.";
RL   J. Biol. Chem. 248:1631-1633(1973).
RN   [14]
RP   ACTIVE SITE.
RX   PubMed=4240117;
RA   Groskopf W.R., Summaria L., Robbins K.C.;
RT   "Studies on the active center of human plasmin. Partial amino acid
RT   sequence of a peptide containing the active center serine residue.";
RL   J. Biol. Chem. 244:3590-3597(1969).
RN   [15]
RP   OMEGA-AMINOCARBOXYLIC ACID-BINDING SITES.
RX   PubMed=6919539;
RA   Trexler M., Vali Z., Patthy L.;
RT   "Structure of the omega-aminocarboxylic acid-binding sites of human
RT   plasminogen. Arginine 70 and aspartic acid 56 are essential for
RT   binding of ligand by kringle 4.";
RL   J. Biol. Chem. 257:7401-7406(1982).
RN   [16]
RP   FIBRIN AND OMEGA-AMINOCARBOXYLIC ACID BINDING SITES.
RX   PubMed=6094526;
RA   Vali Z., Patthy L.;
RT   "The fibrin-binding site of human plasminogen. Arginines 32 and 34 are
RT   essential for fibrin affinity of the kringle 1 domain.";
RL   J. Biol. Chem. 259:13690-13694(1984).
RN   [17]
RP   PHOSPHORYLATION AT SER-597.
RX   PubMed=9201958; DOI=10.1021/bi970328d;
RA   Wang H., Prorok M., Bretthauer R.K., Castellino F.J.;
RT   "Serine-578 is a major phosphorylation locus in human plasma
RT   plasminogen.";
RL   Biochemistry 36:8100-8106(1997).
RN   [18]
RP   GLYCOSYLATION AT SER-268; ASN-308 AND THR-365, AND STRUCTURE OF
RP   CARBOHYDRATES.
RX   PubMed=3356193; DOI=10.1111/j.1432-1033.1988.tb13966.x;
RA   Marti T., Schaller J., Rickli E.E., Schmid K., Kamerling J.P.,
RA   Gerwig G.J., van Halbeek H., Vliegenthart J.F.G.;
RT   "The N- and O-linked carbohydrate chains of human, bovine and porcine
RT   plasminogen. Species specificity in relation to sialylation and
RT   fucosylation patterns.";
RL   Eur. J. Biochem. 173:57-63(1988).
RN   [19]
RP   INTERACTION WITH HRG.
RX   PubMed=9102401; DOI=10.1074/jbc.272.9.5718;
RA   Borza D.B., Morgan W.T.;
RT   "Acceleration of plasminogen activation by tissue plasminogen
RT   activator on surface-bound histidine-proline-rich glycoprotein.";
RL   J. Biol. Chem. 272:5718-5726(1997).
RN   [20]
RP   GLYCOSYLATION AT SER-268.
RX   PubMed=9054441; DOI=10.1074/jbc.272.11.7408;
RA   Pirie-Shepherd S.R., Stevens R.D., Andon N.L., Enghild J.J.,
RA   Pizzo S.V.;
RT   "Evidence for a novel O-linked sialylated trisaccharide on Ser-248 of
RT   human plasminogen 2.";
RL   J. Biol. Chem. 272:7408-7411(1997).
RN   [21]
RP   CHARACTERIZATION OF ANGIOSTATIN, AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=7525077; DOI=10.1016/0092-8674(94)90200-3;
RA   O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A.,
RA   Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J.;
RT   "Angiostatin: a novel angiogenesis inhibitor that mediates the
RT   suppression of metastases by a Lewis lung carcinoma.";
RL   Cell 79:315-328(1994).
RN   [22]
RP   CHARACTERIZATION OF ANGIOSTATIN.
RX   PubMed=9102221;
RA   Sim B.K., O'Reilly M.S., Liang H., Fortier A.H., He W., Madsen J.W.,
RA   Lapcevich R., Nacy C.A.;
RT   "A recombinant human angiostatin protein inhibits experimental primary
RT   and metastatic cancer.";
RL   Cancer Res. 57:1329-1334(1997).
RN   [23]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=9548733; DOI=10.1021/bi9731798;
RA   Lijnen H.R., Ugwu F., Bini A., Collen D.;
RT   "Generation of an angiostatin-like fragment from plasminogen by
RT   stromelysin-1 (MMP-3).";
RL   Biochemistry 37:4699-4702(1998).
RN   [24]
RP   INTERACTION WITH ATP5A1, AND SUBCELLULAR LOCATION.
RX   PubMed=10077593; DOI=10.1073/pnas.96.6.2811;
RA   Moser T.L., Stack M.S., Asplin I., Enghild J.J., Hojrup P.,
RA   Everitt L., Hubchak S., Schnaper H.W., Pizzo S.V.;
RT   "Angiostatin binds ATP synthase on the surface of human endothelial
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2811-2816(1999).
RN   [25]
RP   INTERACTION WITH CSPG4, AND DOMAIN.
RX   PubMed=10889192; DOI=10.1074/jbc.M002290200;
RA   Goretzki L., Lombardo C.R., Stallcup W.B.;
RT   "Binding of the NG2 proteoglycan to kringle domains modulates the
RT   functional properties of angiostatin and plasmin(ogen).";
RL   J. Biol. Chem. 275:28625-28633(2000).
RN   [26]
RP   PROTEOLYTIC PROCESSING, ENZYME REGULATION, SUBCELLULAR LOCATION,
RP   FUNCTION OF PLASMIN, AND MUTAGENESIS OF SER-741.
RX   PubMed=14699093; DOI=10.1074/jbc.M310964200;
RA   Rossignol P., Ho-Tin-Noe B., Vranckx R., Bouton M.C., Meilhac O.,
RA   Lijnen H.R., Guillin M.C., Michel J.B., Angles-Cano E.;
RT   "Protease nexin-1 inhibits plasminogen activation-induced apoptosis of
RT   adherent cells.";
RL   J. Biol. Chem. 279:10346-10356(2004).
RN   [27]
RP   INTERACTION WITH ADA.
RX   PubMed=15016824; DOI=10.1074/jbc.M401023200;
RA   Gonzalez-Gronow M., Hershfield M.S., Arredondo-Vega F.X., Pizzo S.V.;
RT   "Cell surface adenosine deaminase binds and stimulates plasminogen
RT   activation on 1-LN human prostate cancer cells.";
RL   J. Biol. Chem. 279:20993-20998(2004).
RN   [28]
RP   INTERACTION WITH AMOT.
RX   PubMed=16043488; DOI=10.1074/jbc.M503915200;
RA   Bratt A., Birot O., Sinha I., Veitonmaeki N., Aase K., Ernkvist M.,
RA   Holmgren L.;
RT   "Angiomotin regulates endothelial cell-cell junctions and cell
RT   motility.";
RL   J. Biol. Chem. 280:34859-34869(2005).
RN   [29]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-308.
RC   TISSUE=Milk;
RX   PubMed=18780401; DOI=10.1002/pmic.200701057;
RA   Picariello G., Ferranti P., Mamone G., Roepstorff P., Addeo F.;
RT   "Identification of N-linked glycoproteins in human milk by hydrophilic
RT   interaction liquid chromatography and mass spectrometry.";
RL   Proteomics 8:3833-3847(2008).
RN   [30]
RP   CATALYTIC ACTIVITY.
RX   PubMed=2143188;
RA   Kirschbaum N.E., Budzynski A.Z.;
RT   "A unique proteolytic fragment of human fibrinogen containing the A
RT   alpha COOH-terminal domain of the native molecule.";
RL   J. Biol. Chem. 265:13669-13676(1990).
RN   [31]
RP   INTERACTION WITH HRG.
RX   PubMed=19712047; DOI=10.1042/BJ20090794;
RA   Poon I.K., Olsson A.K., Hulett M.D., Parish C.R.;
RT   "Regulation of histidine-rich glycoprotein (HRG) function via plasmin-
RT   mediated proteolytic cleavage.";
RL   Biochem. J. 424:27-37(2009).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 374-461.
RX   PubMed=1657148; DOI=10.1021/bi00107a029;
RA   Mulichak A.M., Tulinsky A., Ravichandran K.G.;
RT   "Crystal and molecular structure of human plasminogen kringle 4
RT   refined at 1.9-A resolution.";
RL   Biochemistry 30:10576-10588(1991).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 374-461.
RX   PubMed=1657149; DOI=10.1021/bi00107a030;
RA   Wu T.-P., Padmanabhan K., Tulinsky A., Mulichak A.M.;
RT   "The refined structure of the epsilon-aminocaproic acid complex of
RT   human plasminogen kringle 4.";
RL   Biochemistry 30:10589-10594(1991).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.48 ANGSTROMS) OF 101-181.
RX   PubMed=8054447;
RA   Wu T.-P., Padmanabhan K.P., Tulinsky A.;
RT   "The structure of recombinant plasminogen kringle 1 and the fibrin
RT   binding site.";
RL   Blood Coagul. Fibrinolysis 5:157-166(1994).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 102-181.
RX   PubMed=8611560; DOI=10.1021/bi9521351;
RA   Mathews I.I., Vanderhoff-Hanaver P., Castellino F.J., Tulinsky A.;
RT   "Crystal structures of the recombinant kringle 1 domain of human
RT   plasminogen in complexes with the ligands epsilon-aminocaproic acid
RT   and trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid.";
RL   Biochemistry 35:2567-2576(1996).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.67 ANGSTROMS) OF 376-454.
RX   PubMed=15299951; DOI=10.1107/S0907444996012267;
RA   Stec B., Yamano A., Whitlow M., Teeter M.M.;
RT   "Structure of human plasminogen kringle 4 at 1.68 Angstrom and 277 K.
RT   A possible structural role of disordered residues.";
RL   Acta Crystallogr. D 53:169-178(1997).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 561-810, AND DISULFIDE
RP   BONDS.
RX   PubMed=9783753; DOI=10.1038/2359;
RA   Parry M.A., Fernandez-Catalan C., Bergner A., Huber R., Hopfner K.P.,
RA   Schlott B., Guehrs K.H., Bode W.;
RT   "The ternary microplasmin-staphylokinase-microplasmin complex is a
RT   proteinase-cofactor-substrate complex in action.";
RL   Nat. Struct. Biol. 5:917-923(1998).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.66 ANGSTROMS) OF 480-563.
RX   PubMed=9521645; DOI=10.1021/bi972284e;
RA   Chang Y., Mochalkin I., McCance S.G., Cheng B., Tulinsky A.,
RA   Castellino F.J.;
RT   "Structure and ligand binding determinants of the recombinant kringle
RT   5 domain of human plasminogen.";
RL   Biochemistry 37:3258-3271(1998).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 564-810, AND DISULFIDE BONDS.
RX   PubMed=10656799; DOI=10.1006/jmbi.1999.3397;
RA   Wang X., Terzyan S., Tang J., Loy J.A., Lin X., Zhang X.C.;
RT   "Human plasminogen catalytic domain undergoes an unusual
RT   conformational change upon activation.";
RL   J. Mol. Biol. 295:903-914(2000).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 183-262.
RX   PubMed=11350170; DOI=10.1006/jmbi.2001.4646;
RA   Rios-Steiner J.L., Schenone M., Mochalkin I., Tulinsky A.,
RA   Castellino F.J.;
RT   "Structure and binding determinants of the recombinant kringle-2
RT   domain of human plasminogen to an internal peptide from a group A
RT   Streptococcal surface protein.";
RL   J. Mol. Biol. 308:705-719(2001).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 100-352, AND DISULFIDE
RP   BONDS.
RX   PubMed=12054798; DOI=10.1016/S0022-2836(02)00211-5;
RA   Abad M.C., Arni R.K., Grella D.K., Castellino F.J., Tulinsky A.,
RA   Geiger J.H.;
RT   "The X-ray crystallographic structure of the angiogenesis inhibitor
RT   angiostatin.";
RL   J. Mol. Biol. 318:1009-1017(2002).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 562-810.
RX   PubMed=12456874; DOI=10.1093/protein/15.9.753;
RA   Wakeham N., Terzyan S., Zhai P., Loy J.A., Tang J., Zhang X.C.;
RT   "Effects of deletion of streptokinase residues 48-59 on plasminogen
RT   activation.";
RL   Protein Eng. 15:753-761(2002).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 564-810.
RX   PubMed=15211511; DOI=10.1002/prot.20070;
RA   Terzyan S., Wakeham N., Zhai P., Rodgers K., Zhang X.C.;
RT   "Characterization of Lys-698-to-Met substitution in human plasminogen
RT   catalytic domain.";
RL   Proteins 56:277-284(2004).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.78 ANGSTROMS) OF 564-810 IN COMPLEX WITH THE
RP   SNAKE VENOM PROTEASE INHIBITOR TEXTILININ-1, AND DISULFIDE BOND.
RX   PubMed=23335990; DOI=10.1371/journal.pone.0054104;
RA   Millers E.K., Johnson L.A., Birrell G.W., Masci P.P., Lavin M.F.,
RA   de Jersey J., Guddat L.W.;
RT   "The structure of human microplasmin in complex with textilinin-1, an
RT   aprotinin-like inhibitor from the Australian brown snake.";
RL   PLoS ONE 8:E54104-E54104(2013).
RN   [46]
RP   STRUCTURE BY NMR OF 374-461.
RX   PubMed=2157850; DOI=10.1016/0022-2836(90)90330-O;
RA   Atkinson R.A., Williams R.J.P.;
RT   "Solution structure of the kringle 4 domain from human plasminogen by
RT   1H nuclear magnetic resonance spectroscopy and distance geometry.";
RL   J. Mol. Biol. 212:541-552(1990).
RN   [47]
RP   STRUCTURE BY NMR OF 96-184.
RX   PubMed=8181475; DOI=10.1111/j.1432-1033.1994.tb18808.x;
RA   Rejante M.R., Llinas M.;
RT   "1H-NMR assignments and secondary structure of human plasminogen
RT   kringle 1.";
RL   Eur. J. Biochem. 221:927-937(1994).
RN   [48]
RP   STRUCTURE BY NMR OF 96-184.
RX   PubMed=8181476; DOI=10.1111/j.1432-1033.1994.tb18809.x;
RA   Rejante M.R., Llinas M.;
RT   "Solution structure of the epsilon-aminohexanoic acid complex of human
RT   plasminogen kringle 1.";
RL   Eur. J. Biochem. 221:939-949(1994).
RN   [49]
RP   STRUCTURE BY NMR OF 183-354.
RX   PubMed=8652577; DOI=10.1021/bi9520949;
RA   Soehndel S., Hu C.-K., Marti D., Affolter M., Schaller J., Llinas M.,
RA   Rickli E.E.;
RT   "Recombinant gene expression and 1H NMR characteristics of the kringle
RT   (2 + 3) supermodule: spectroscopic/functional individuality of
RT   plasminogen kringle domains.";
RL   Biochemistry 35:2357-2364(1996).
RN   [50]
RP   STRUCTURE BY NMR OF 183-263.
RX   PubMed=9305949; DOI=10.1021/bi971316v;
RA   Marti D.N., Hu C.K., An S.S., von Haller P., Schaller J., Llinas M.;
RT   "Ligand preferences of kringle 2 and homologous domains of human
RT   plasminogen: canvassing weak, intermediate, and high-affinity binding
RT   sites by 1H-NMR.";
RL   Biochemistry 36:11591-11604(1997).
RN   [51]
RP   VARIANTS PLGD PHE-374 AND THR-620.
RX   PubMed=1986355; DOI=10.1073/pnas.88.1.115;
RA   Ichinose A., Espling E.S., Takamatsu J., Saito H., Shinmyozu K.,
RA   Maruyama I., Petersen T.E., Davie E.W.;
RT   "Two types of abnormal genes for plasminogen in families with a
RT   predisposition for thrombosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:115-119(1991).
RN   [52]
RP   ERRATUM.
RA   Ichinose A., Espling E.S., Takamatsu J., Saito H., Shinmyozu K.,
RA   Maruyama I., Petersen T.E., Davie E.W.;
RL   Proc. Natl. Acad. Sci. U.S.A. 88:2067-2067(1991).
RN   [53]
RP   VARIANT PLGD PRO-591.
RX   PubMed=8392398;
RA   Azuma H., Uno Y., Shigekiyo T., Saito S.;
RT   "Congenital plasminogen deficiency caused by a Ser-572 to Pro
RT   mutation.";
RL   Blood 82:475-480(1993).
RN   [54]
RP   VARIANT PLGD THR-620.
RX   PubMed=6216475; DOI=10.1073/pnas.79.20.6132;
RA   Miyata T., Iwanaga S., Sakata Y., Aoki N.;
RT   "Plasminogen Tochigi: inactive plasmin resulting from replacement of
RT   alanine-600 by threonine in the active site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:6132-6136(1982).
RN   [55]
RP   VARIANT PLGD THR-620.
RX   PubMed=6238949;
RA   Miyata T., Iwanaga S., Sakata Y., Aoki N., Takamatsu J., Kamiya T.;
RT   "Plasminogens Tochigi II and Nagoya: two additional molecular defects
RT   with Ala-600-->Thr replacement found in plasmin light chain
RT   variants.";
RL   J. Biochem. 96:277-287(1984).
RN   [56]
RP   VARIANT PLGD THR-620.
RX   PubMed=1427790; DOI=10.1007/BF00210737;
RA   Kikuchi S., Yamanouchi Y., Li L., Kobayashi K., Ijima H., Miyazaki R.,
RA   Tsuchiya S., Hamaguchi H.;
RT   "Plasminogen with type-I mutation is polymorphic in the Japanese
RT   population.";
RL   Hum. Genet. 90:7-11(1992).
RN   [57]
RP   VARIANT PLGD HIS-235.
RX   PubMed=9242524;
RA   Schuster V., Mingers A.-M., Seidenspinner S., Nuessgens Z., Pukrop T.,
RA   Kreth H.W.;
RT   "Homozygous mutations in the plasminogen gene of two unrelated girls
RT   with ligneous conjunctivitis.";
RL   Blood 90:958-966(1997).
RN   [58]
RP   VARIANT PLGD ARG-751.
RX   PubMed=9858247; DOI=10.1046/j.1365-2141.1998.01074.x;
RA   Higuchi Y., Furihata K., Ueno I., Ishikawa S., Okumura N., Tozuka M.,
RA   Sakurai N.;
RT   "Plasminogen Kanagawa-I, a novel missense mutation, is caused by the
RT   amino acid substitution G732R.";
RL   Br. J. Haematol. 103:867-870(1998).
RN   [59]
RP   VARIANTS PLGD GLU-38; PRO-147 AND HIS-532.
RX   PubMed=10233898;
RA   Schuster V., Seidenspinner S., Zeitler P., Escher C., Pleyer U.,
RA   Bernauer W., Stiehm E.R., Isenberg S., Seregard S., Olsson T.,
RA   Mingers A.-M., Schambeck C., Kreth H.W.;
RT   "Compound-heterozygous mutations in the plasminogen gene predispose to
RT   the development of ligneous conjunctivitis.";
RL   Blood 93:3457-3466(1999).
CC   -!- FUNCTION: Plasmin dissolves the fibrin of blood clots and acts as
CC       a proteolytic factor in a variety of other processes including
CC       embryonic development, tissue remodeling, tumor invasion, and
CC       inflammation. In ovulation, weakens the walls of the Graafian
CC       follicle. It activates the urokinase-type plasminogen activator,
CC       collagenases and several complement zymogens, such as C1 and C5.
CC       Cleavage of fibronectin and laminin leads to cell detachment and
CC       apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand
CC       factor. Its role in tissue remodeling and tumor invasion may be
CC       modulated by CSPG4. Binds to cells. {ECO:0000269|PubMed:14699093}.
CC   -!- FUNCTION: Angiostatin is an angiogenesis inhibitor that blocks
CC       neovascularization and growth of experimental primary and
CC       metastatic tumors in vivo. {ECO:0000269|PubMed:14699093}.
CC   -!- CATALYTIC ACTIVITY: Preferential cleavage: Lys-|-Xaa > Arg-|-Xaa;
CC       higher selectivity than trypsin. Converts fibrin into soluble
CC       products. {ECO:0000269|PubMed:2143188}.
CC   -!- ENZYME REGULATION: Converted into plasmin by plasminogen
CC       activators, both plasminogen and its activator being bound to
CC       fibrin. Activated with catalytic amounts of streptokinase. Plasmin
CC       activity inhibited by SERPINE2. {ECO:0000269|PubMed:14699093}.
CC   -!- SUBUNIT: Interacts (both mature PLG and the angiostatin peptide)
CC       with CSPG4 and AMOT (PubMed:10889192, PubMed:16043488). Interacts
CC       (via the Kringle domains) with HRG; the interaction tethers PLG to
CC       the cell surface and enhances its activation (PubMed:9102401,
CC       PubMed:19712047). Interacts (via Kringle 4 domain) with ADA; the
CC       interaction stimulates PLG activation when in complex with DPP4
CC       (PubMed:15016824). Angiostatin: Interacts with ATP5A1; the
CC       interaction inhibits most of the angiogenic effects of angiostatin
CC       (PubMed:10077593). {ECO:0000269|PubMed:10077593,
CC       ECO:0000269|PubMed:10889192, ECO:0000269|PubMed:15016824,
CC       ECO:0000269|PubMed:16043488, ECO:0000269|PubMed:19712047,
CC       ECO:0000269|PubMed:9102401}.
CC   -!- INTERACTION:
CC       Q6V4L1:- (xeno); NbExp=2; IntAct=EBI-999394, EBI-984250;
CC       Q6V4L4:- (xeno); NbExp=2; IntAct=EBI-999394, EBI-984286;
CC       Q6V4L5:- (xeno); NbExp=2; IntAct=EBI-999394, EBI-984118;
CC       Q6V4L9:- (xeno); NbExp=2; IntAct=EBI-999394, EBI-984197;
CC       P02749:APOH; NbExp=2; IntAct=EBI-999394, EBI-2114682;
CC       P75390:pdhA (xeno); NbExp=5; IntAct=EBI-999394, EBI-2259629;
CC       P75391:pdhB (xeno); NbExp=11; IntAct=EBI-999394, EBI-2259621;
CC       P75392:pdhC (xeno); NbExp=5; IntAct=EBI-999394, EBI-2259593;
CC       P75393:pdhD (xeno); NbExp=3; IntAct=EBI-999394, EBI-2259617;
CC       Q99SU7:sak (xeno); NbExp=7; IntAct=EBI-999394, EBI-7689378;
CC       P00779:skc (xeno); NbExp=2; IntAct=EBI-999394, EBI-1035089;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10077593,
CC       ECO:0000269|PubMed:14699093}. Note=Locates to the cell surface
CC       where it is proteolytically cleaved to produce the active plasmin.
CC       Interaction with HRG tethers it to the cell surface.
CC   -!- TISSUE SPECIFICITY: Present in plasma and many other extracellular
CC       fluids. It is synthesized in the liver.
CC   -!- DOMAIN: Kringle domains mediate interaction with CSPG4.
CC       {ECO:0000269|PubMed:10889192}.
CC   -!- PTM: N-linked glycan contains N-acetyllactosamine and sialic acid.
CC       O-linked glycans consist of Gal-GalNAc disaccharide modified with
CC       up to 2 sialic acid residues (microheterogeneity).
CC       {ECO:0000269|PubMed:18780401, ECO:0000269|PubMed:3356193,
CC       ECO:0000269|PubMed:9054441}.
CC   -!- PTM: In the presence of the inhibitor, the activation involves
CC       only cleavage after Arg-580, yielding two chains held together by
CC       two disulfide bonds. In the absence of the inhibitor, the
CC       activation involves additionally the removal of the activation
CC       peptide. {ECO:0000269|PubMed:14699093,
CC       ECO:0000269|PubMed:9548733}.
CC   -!- DISEASE: Plasminogen deficiency (PLGD) [MIM:217090]: A disorder
CC       characterized by decreased serum plasminogen activity. Two forms
CC       of the disorder are distinguished: type 1 deficiency is
CC       additionally characterized by decreased plasminogen antigen levels
CC       and clinical symptoms, whereas type 2 deficiency, also known as
CC       dysplasminogenemia, is characterized by normal, or slightly
CC       reduced antigen levels, and absence of clinical manifestations.
CC       Plasminogen deficiency type 1 results in markedly impaired
CC       extracellular fibrinolysis and chronic mucosal pseudomembranous
CC       lesions due to subepithelial fibrin deposition and inflammation.
CC       The most common clinical manifestation of type 1 deficiency is
CC       ligneous conjunctivitis in which pseudomembranes formation on the
CC       palpebral surfaces of the eye progresses to white, yellow-white,
CC       or red thick masses with a wood-like consistency that replace the
CC       normal mucosa. {ECO:0000269|PubMed:10233898,
CC       ECO:0000269|PubMed:1427790, ECO:0000269|PubMed:1986355,
CC       ECO:0000269|PubMed:6216475, ECO:0000269|PubMed:6238949,
CC       ECO:0000269|PubMed:8392398, ECO:0000269|PubMed:9242524,
CC       ECO:0000269|PubMed:9858247}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Plasmin is inactivated by alpha-2-antiplasmin
CC       immediately after dissociation from the clot.
CC   -!- SIMILARITY: Belongs to the peptidase S1 family. Plasminogen
CC       subfamily. {ECO:0000255|PROSITE-ProRule:PRU00274}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Plasmin entry;
CC       URL="https://en.wikipedia.org/wiki/Plasmin";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/plg/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M34276; AAA60113.1; -; Genomic_DNA.
DR   EMBL; M33272; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33274; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33275; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33278; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33279; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33280; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33282; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33283; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33284; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33285; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33286; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33287; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33288; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33289; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33290; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M34272; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M34273; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M34275; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; X05199; CAA28831.1; -; mRNA.
DR   EMBL; M74220; AAA36451.1; -; mRNA.
DR   EMBL; AY192161; AAN85555.1; -; Genomic_DNA.
DR   EMBL; AL109933; CAI22908.1; -; Genomic_DNA.
DR   EMBL; BC060513; AAH60513.1; -; mRNA.
DR   EMBL; K02922; AAA60124.1; -; mRNA.
DR   CCDS; CCDS5279.1; -.
DR   PIR; A35229; PLHU.
DR   RefSeq; NP_000292.1; NM_000301.3.
DR   UniGene; Hs.143436; -.
DR   PDB; 1B2I; NMR; -; A=181-263.
DR   PDB; 1BML; X-ray; 2.90 A; A/B=561-810.
DR   PDB; 1BUI; X-ray; 2.65 A; A/B=561-810.
DR   PDB; 1CEA; X-ray; 2.06 A; A/B=100-187.
DR   PDB; 1CEB; X-ray; 2.07 A; A/B=100-187.
DR   PDB; 1DDJ; X-ray; 2.00 A; A/B/C/D=564-810.
DR   PDB; 1HPJ; NMR; -; A=103-181.
DR   PDB; 1HPK; NMR; -; A=103-181.
DR   PDB; 1I5K; X-ray; 2.70 A; A/B=184-262.
DR   PDB; 1KI0; X-ray; 1.75 A; A=100-352.
DR   PDB; 1KRN; X-ray; 1.67 A; A=374-461.
DR   PDB; 1L4D; X-ray; 2.30 A; A=562-810.
DR   PDB; 1L4Z; X-ray; 2.80 A; A=563-810.
DR   PDB; 1PK4; X-ray; 1.90 A; A=376-454.
DR   PDB; 1PKR; X-ray; 2.48 A; A=101-181.
DR   PDB; 1PMK; X-ray; 2.25 A; A/B=374-461.
DR   PDB; 1QRZ; X-ray; 2.00 A; A/B/C/D=565-810.
DR   PDB; 1RJX; X-ray; 2.30 A; B=564-810.
DR   PDB; 2DOH; X-ray; 2.30 A; X=100-333.
DR   PDB; 2DOI; X-ray; 3.10 A; A/X=100-333.
DR   PDB; 2KNF; NMR; -; A=480-562.
DR   PDB; 2L0S; NMR; -; A=272-354.
DR   PDB; 2PK4; X-ray; 2.25 A; A=375-454.
DR   PDB; 3UIR; X-ray; 2.78 A; A/B=564-810.
DR   PDB; 4A5T; X-ray; 3.49 A; S=20-810.
DR   PDB; 4CIK; X-ray; 1.78 A; A=101-181.
DR   PDB; 4DCB; X-ray; 2.03 A; F=576-585.
DR   PDB; 4DUR; X-ray; 2.45 A; A/B=20-810.
DR   PDB; 4DUU; X-ray; 5.20 A; A=20-810.
DR   PDB; 5HPG; X-ray; 1.66 A; A/B=480-563.
DR   PDBsum; 1B2I; -.
DR   PDBsum; 1BML; -.
DR   PDBsum; 1BUI; -.
DR   PDBsum; 1CEA; -.
DR   PDBsum; 1CEB; -.
DR   PDBsum; 1DDJ; -.
DR   PDBsum; 1HPJ; -.
DR   PDBsum; 1HPK; -.
DR   PDBsum; 1I5K; -.
DR   PDBsum; 1KI0; -.
DR   PDBsum; 1KRN; -.
DR   PDBsum; 1L4D; -.
DR   PDBsum; 1L4Z; -.
DR   PDBsum; 1PK4; -.
DR   PDBsum; 1PKR; -.
DR   PDBsum; 1PMK; -.
DR   PDBsum; 1QRZ; -.
DR   PDBsum; 1RJX; -.
DR   PDBsum; 2DOH; -.
DR   PDBsum; 2DOI; -.
DR   PDBsum; 2KNF; -.
DR   PDBsum; 2L0S; -.
DR   PDBsum; 2PK4; -.
DR   PDBsum; 3UIR; -.
DR   PDBsum; 4A5T; -.
DR   PDBsum; 4CIK; -.
DR   PDBsum; 4DCB; -.
DR   PDBsum; 4DUR; -.
DR   PDBsum; 4DUU; -.
DR   PDBsum; 5HPG; -.
DR   DisProt; DP00191; -.
DR   ProteinModelPortal; P00747; -.
DR   SMR; P00747; -.
DR   BioGrid; 111356; 35.
DR   IntAct; P00747; 41.
DR   STRING; 9606.ENSP00000308938; -.
DR   BindingDB; P00747; -.
DR   ChEMBL; CHEMBL1801; -.
DR   DrugBank; DB00009; Alteplase.
DR   DrugBank; DB00513; Aminocaproic Acid.
DR   DrugBank; DB00029; Anistreplase.
DR   DrugBank; DB06692; Aprotinin.
DR   DrugBank; DB03709; Bicine.
DR   DrugBank; DB04925; Desmoteplase.
DR   DrugBank; DB00015; Reteplase.
DR   DrugBank; DB00086; Streptokinase.
DR   DrugBank; DB00031; Tenecteplase.
DR   DrugBank; DB00302; Tranexamic Acid.
DR   DrugBank; DB00013; Urokinase.
DR   GuidetoPHARMACOLOGY; 2394; -.
DR   MEROPS; S01.233; -.
DR   iPTMnet; P00747; -.
DR   PhosphoSitePlus; P00747; -.
DR   UniCarbKB; P00747; -.
DR   BioMuta; PLG; -.
DR   DMDM; 130316; -.
DR   SWISS-2DPAGE; P00747; -.
DR   EPD; P00747; -.
DR   MaxQB; P00747; -.
DR   PaxDb; P00747; -.
DR   PeptideAtlas; P00747; -.
DR   PRIDE; P00747; -.
DR   Ensembl; ENST00000308192; ENSP00000308938; ENSG00000122194.
DR   GeneID; 5340; -.
DR   KEGG; hsa:5340; -.
DR   UCSC; uc003qtm.5; human.
DR   CTD; 5340; -.
DR   DisGeNET; 5340; -.
DR   GeneCards; PLG; -.
DR   HGNC; HGNC:9071; PLG.
DR   HPA; CAB000668; -.
DR   HPA; CAB016678; -.
DR   HPA; HPA021602; -.
DR   HPA; HPA048823; -.
DR   HPA; HPA053770; -.
DR   MalaCards; PLG; -.
DR   MIM; 173350; gene.
DR   MIM; 217090; phenotype.
DR   neXtProt; NX_P00747; -.
DR   OpenTargets; ENSG00000122194; -.
DR   Orphanet; 722; Hypoplasminogenemia.
DR   Orphanet; 97231; Ligneous conjunctivitis.
DR   PharmGKB; PA33405; -.
DR   eggNOG; ENOG410IDXR; Eukaryota.
DR   eggNOG; COG5640; LUCA.
DR   GeneTree; ENSGT00760000119133; -.
DR   HOGENOM; HOG000112892; -.
DR   HOVERGEN; HBG004381; -.
DR   InParanoid; P00747; -.
DR   KO; K01315; -.
DR   OMA; FPNKNLK; -.
DR   OrthoDB; EOG091G0AH5; -.
DR   PhylomeDB; P00747; -.
DR   TreeFam; TF329901; -.
DR   BioCyc; MetaCyc:HS04553-MONOMER; -.
DR   BRENDA; 3.4.21.7; 2681.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-1592389; Activation of Matrix Metalloproteinases.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-75205; Dissolution of Fibrin Clot.
DR   SABIO-RK; P00747; -.
DR   ChiTaRS; PLG; human.
DR   EvolutionaryTrace; P00747; -.
DR   GeneWiki; Plasmin; -.
DR   GeneWiki; Plasminogen_activator; -.
DR   GenomeRNAi; 5340; -.
DR   PMAP-CutDB; P00747; -.
DR   PRO; PR:P00747; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000122194; -.
DR   CleanEx; HS_PLG; -.
DR   ExpressionAtlas; P00747; baseline and differential.
DR   Genevisible; P00747; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0031232; C:extrinsic component of external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0044218; C:other organism cell membrane; IDA:CAFA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0034185; F:apolipoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0051087; F:chaperone binding; IPI:CAFA.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:CAFA.
DR   GO; GO:0019899; F:enzyme binding; IPI:CAFA.
DR   GO; GO:0019900; F:kinase binding; IPI:CAFA.
DR   GO; GO:1904854; F:proteasome core complex binding; IPI:CAFA.
DR   GO; GO:1990405; F:protein antigen binding; IPI:CAFA.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IPI:AgBase.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IDA:CAFA.
DR   GO; GO:0008236; F:serine-type peptidase activity; TAS:AgBase.
DR   GO; GO:0007596; P:blood coagulation; IMP:HGNC.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0022617; P:extracellular matrix disassembly; IDA:BHF-UCL.
DR   GO; GO:0042730; P:fibrinolysis; IDA:CAFA.
DR   GO; GO:0051702; P:interaction with symbiont; IDA:CAFA.
DR   GO; GO:0052213; P:interaction with symbiont via secreted substance involved in symbiotic interaction; IDA:CAFA.
DR   GO; GO:0052182; P:modification by host of symbiont morphology or physiology via secreted substance; IDA:CAFA.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:2000048; P:negative regulation of cell-cell adhesion mediated by cadherin; TAS:BHF-UCL.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; IDA:BHF-UCL.
DR   GO; GO:0051918; P:negative regulation of fibrinolysis; IDA:BHF-UCL.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IGI:CAFA.
DR   GO; GO:0051919; P:positive regulation of fibrinolysis; IDA:AgBase.
DR   GO; GO:0006508; P:proteolysis; IDA:CAFA.
DR   GO; GO:0048771; P:tissue remodeling; IEA:UniProtKB-KW.
DR   CDD; cd00190; Tryp_SPc; 1.
DR   InterPro; IPR000001; Kringle.
DR   InterPro; IPR013806; Kringle-like.
DR   InterPro; IPR018056; Kringle_CS.
DR   InterPro; IPR003609; Pan_app.
DR   InterPro; IPR023317; Pept_S1A_plasmin.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR001314; Peptidase_S1A.
DR   InterPro; IPR001254; Trypsin_dom.
DR   InterPro; IPR018114; TRYPSIN_HIS.
DR   InterPro; IPR033116; TRYPSIN_SER.
DR   Pfam; PF00051; Kringle; 5.
DR   Pfam; PF00024; PAN_1; 1.
DR   Pfam; PF00089; Trypsin; 1.
DR   PIRSF; PIRSF001150; Plasmin; 1.
DR   PRINTS; PR00722; CHYMOTRYPSIN.
DR   SMART; SM00130; KR; 5.
DR   SMART; SM00473; PAN_AP; 1.
DR   SMART; SM00020; Tryp_SPc; 1.
DR   SUPFAM; SSF50494; SSF50494; 1.
DR   SUPFAM; SSF57440; SSF57440; 5.
DR   PROSITE; PS00021; KRINGLE_1; 5.
DR   PROSITE; PS50070; KRINGLE_2; 5.
DR   PROSITE; PS50948; PAN; 1.
DR   PROSITE; PS50240; TRYPSIN_DOM; 1.
DR   PROSITE; PS00134; TRYPSIN_HIS; 1.
DR   PROSITE; PS00135; TRYPSIN_SER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Blood coagulation; Cleavage on pair of basic residues;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Fibrinolysis; Glycoprotein; Hemostasis; Hydrolase;
KW   Kringle; Phosphoprotein; Polymorphism; Protease; Reference proteome;
KW   Repeat; Secreted; Serine protease; Signal; Thrombophilia;
KW   Tissue remodeling; Zymogen.
FT   SIGNAL        1     19       {ECO:0000269|PubMed:122932,
FT                                ECO:0000269|Ref.7}.
FT   CHAIN        20    810       Plasminogen.
FT                                /FTId=PRO_0000028053.
FT   CHAIN        20    580       Plasmin heavy chain A.
FT                                /FTId=PRO_0000028054.
FT   PEPTIDE      20     97       Activation peptide.
FT                                /FTId=PRO_0000028055.
FT   CHAIN        79    466       Angiostatin.
FT                                /FTId=PRO_0000028057.
FT   CHAIN        98    580       Plasmin heavy chain A, short form.
FT                                /FTId=PRO_0000028056.
FT   CHAIN       581    810       Plasmin light chain B.
FT                                /FTId=PRO_0000028058.
FT   DOMAIN       20     98       PAN. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00315}.
FT   DOMAIN      103    181       Kringle 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00121}.
FT   DOMAIN      184    262       Kringle 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00121}.
FT   DOMAIN      275    352       Kringle 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00121}.
FT   DOMAIN      377    454       Kringle 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00121}.
FT   DOMAIN      481    560       Kringle 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00121}.
FT   DOMAIN      581    808       Peptidase S1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00274}.
FT   ACT_SITE    622    622       Charge relay system.
FT   ACT_SITE    665    665       Charge relay system.
FT   ACT_SITE    760    760       Charge relay system.
FT   BINDING     134    134       Fibrin.
FT   BINDING     136    136       Fibrin.
FT   BINDING     136    136       Omega-aminocarboxylic acids.
FT   BINDING     158    158       Omega-aminocarboxylic acids.
FT   BINDING     172    172       Omega-aminocarboxylic acids.
FT   BINDING     432    432       Omega-aminocarboxylic acids.
FT   BINDING     445    445       Omega-aminocarboxylic acids.
FT   SITE         78     79       Cleavage; by stromelysin-1.
FT   SITE        466    467       Cleavage; by stromelysin-19.
FT   SITE        580    581       Cleavage; by plasminogen activator.
FT   MOD_RES     597    597       Phosphoserine.
FT                                {ECO:0000269|PubMed:9201958}.
FT   MOD_RES     688    688       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD    268    268       O-linked (GalNAc...) serine.
FT                                {ECO:0000269|PubMed:3356193,
FT                                ECO:0000269|PubMed:9054441}.
FT                                /FTId=CAR_000016.
FT   CARBOHYD    308    308       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:18780401,
FT                                ECO:0000269|PubMed:3356193}.
FT                                /FTId=CAR_000017.
FT   CARBOHYD    365    365       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:3356193}.
FT                                /FTId=CAR_000018.
FT   DISULFID     49     73
FT   DISULFID     53     61
FT   DISULFID    103    181
FT   DISULFID    124    164
FT   DISULFID    152    176
FT   DISULFID    185    262
FT   DISULFID    188    316
FT   DISULFID    206    245
FT   DISULFID    234    257
FT   DISULFID    275    352
FT   DISULFID    296    335
FT   DISULFID    324    347
FT   DISULFID    377    454
FT   DISULFID    398    437
FT   DISULFID    426    449
FT   DISULFID    481    560
FT   DISULFID    502    543
FT   DISULFID    531    555
FT   DISULFID    567    685       Interchain (between A and B chains).
FT   DISULFID    577    585       Interchain (between A and B chains).
FT   DISULFID    607    623
FT   DISULFID    699    766
FT   DISULFID    729    745
FT   DISULFID    756    784
FT   VARIANT      38     38       K -> E (in PLGD; common mutation;
FT                                dbSNP:rs73015965).
FT                                {ECO:0000269|PubMed:10233898}.
FT                                /FTId=VAR_018657.
FT   VARIANT      46     46       I -> R (in dbSNP:rs1049573).
FT                                /FTId=VAR_011779.
FT   VARIANT      57     57       E -> K (in dbSNP:rs4252070).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016287.
FT   VARIANT     133    133       H -> Q (in dbSNP:rs4252186).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016288.
FT   VARIANT     134    134       R -> K (in dbSNP:rs2817).
FT                                /FTId=VAR_033653.
FT   VARIANT     147    147       L -> P (in PLGD; dbSNP:rs770198253).
FT                                {ECO:0000269|PubMed:10233898}.
FT                                /FTId=VAR_018658.
FT   VARIANT     235    235       R -> H (in PLGD; severe type 1
FT                                deficiency; dbSNP:rs121918030).
FT                                {ECO:0000269|PubMed:9242524}.
FT                                /FTId=VAR_018659.
FT   VARIANT     261    261       R -> H (in dbSNP:rs4252187).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016289.
FT   VARIANT     374    374       V -> F (in PLGD; Nagoya-1;
FT                                dbSNP:rs121918028).
FT                                {ECO:0000269|PubMed:1986355}.
FT                                /FTId=VAR_006627.
FT   VARIANT     408    408       R -> W (in dbSNP:rs4252119).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016290.
FT   VARIANT     453    453       K -> I (in dbSNP:rs1804181).
FT                                /FTId=VAR_011780.
FT   VARIANT     472    472       D -> N (in dbSNP:rs4252125).
FT                                {ECO:0000269|PubMed:2318848,
FT                                ECO:0000269|Ref.4, ECO:0000269|Ref.7,
FT                                ECO:0000269|Ref.9}.
FT                                /FTId=VAR_016291.
FT   VARIANT     494    494       A -> V (in dbSNP:rs4252128).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016292.
FT   VARIANT     523    523       R -> W (in dbSNP:rs4252129).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016293.
FT   VARIANT     532    532       R -> H (in PLGD).
FT                                {ECO:0000269|PubMed:10233898}.
FT                                /FTId=VAR_018660.
FT   VARIANT     591    591       S -> P (in PLGD; may be associated with
FT                                susceptibility to thrombosis;
FT                                dbSNP:rs121918029).
FT                                {ECO:0000269|PubMed:8392398}.
FT                                /FTId=VAR_006628.
FT   VARIANT     620    620       A -> T (in PLGD; type 2 plasminogen
FT                                deficiency; decreased activity; Nagoya-2/
FT                                Tochigi/Kagoshima; may be associated with
FT                                susceptibility to thrombosis;
FT                                dbSNP:rs121918027).
FT                                {ECO:0000269|PubMed:1427790,
FT                                ECO:0000269|PubMed:1986355,
FT                                ECO:0000269|PubMed:6216475,
FT                                ECO:0000269|PubMed:6238949}.
FT                                /FTId=VAR_006629.
FT   VARIANT     676    676       V -> D (in dbSNP:rs17857492).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_031213.
FT   VARIANT     751    751       G -> R (in PLGD; Kanagawa-1; 50%
FT                                activity; dbSNP:rs121918033).
FT                                {ECO:0000269|PubMed:9858247}.
FT                                /FTId=VAR_006630.
FT   MUTAGEN     741    741       S->A: Proteolytically cleaved, but
FT                                abolishes plasmin activity and cell
FT                                detachment.
FT                                {ECO:0000269|PubMed:14699093}.
FT   CONFLICT     50     50       A -> AQ (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     72     72       Q -> E (in Ref. 7; AA sequence and 8; AA
FT                                sequence). {ECO:0000305}.
FT   CONFLICT     86     86       Missing (in Ref. 7; AA sequence and 8; AA
FT                                sequence). {ECO:0000305}.
FT   CONFLICT    361    361       Q -> E (in Ref. 7; AA sequence and 9; AA
FT                                sequence). {ECO:0000305}.
FT   CONFLICT    701    701       I -> V (in Ref. 3; AAA36451).
FT                                {ECO:0000305}.
FT   STRAND       25     33       {ECO:0000244|PDB:4DUR}.
FT   STRAND       36     42       {ECO:0000244|PDB:4DUR}.
FT   HELIX        46     55       {ECO:0000244|PDB:4DUR}.
FT   STRAND       57     59       {ECO:0000244|PDB:4DUR}.
FT   STRAND       63     67       {ECO:0000244|PDB:4DUR}.
FT   TURN         68     71       {ECO:0000244|PDB:4DUR}.
FT   STRAND       72     77       {ECO:0000244|PDB:4DUR}.
FT   TURN         80     82       {ECO:0000244|PDB:4DUR}.
FT   STRAND       85     96       {ECO:0000244|PDB:4DUR}.
FT   HELIX        97     99       {ECO:0000244|PDB:4DUR}.
FT   STRAND      102    104       {ECO:0000244|PDB:1KI0}.
FT   STRAND      105    110       {ECO:0000244|PDB:1HPJ}.
FT   HELIX       113    115       {ECO:0000244|PDB:1HPJ}.
FT   TURN        119    121       {ECO:0000244|PDB:1HPJ}.
FT   STRAND      131    133       {ECO:0000244|PDB:1KI0}.
FT   TURN        139    141       {ECO:0000244|PDB:1KI0}.
FT   TURN        143    146       {ECO:0000244|PDB:4CIK}.
FT   STRAND      148    150       {ECO:0000244|PDB:1HPJ}.
FT   STRAND      155    157       {ECO:0000244|PDB:1HPK}.
FT   STRAND      163    167       {ECO:0000244|PDB:1KI0}.
FT   STRAND      172    175       {ECO:0000244|PDB:1KI0}.
FT   STRAND      180    182       {ECO:0000244|PDB:2DOH}.
FT   STRAND      184    186       {ECO:0000244|PDB:1KI0}.
FT   STRAND      205    207       {ECO:0000244|PDB:1I5K}.
FT   STRAND      209    211       {ECO:0000244|PDB:1B2I}.
FT   STRAND      213    215       {ECO:0000244|PDB:1KI0}.
FT   TURN        221    223       {ECO:0000244|PDB:1KI0}.
FT   HELIX       225    227       {ECO:0000244|PDB:2DOH}.
FT   STRAND      237    239       {ECO:0000244|PDB:1KI0}.
FT   STRAND      244    248       {ECO:0000244|PDB:1KI0}.
FT   STRAND      253    256       {ECO:0000244|PDB:1KI0}.
FT   STRAND      273    276       {ECO:0000244|PDB:1KI0}.
FT   STRAND      281    283       {ECO:0000244|PDB:2L0S}.
FT   STRAND      291    293       {ECO:0000244|PDB:2L0S}.
FT   STRAND      295    297       {ECO:0000244|PDB:4DUR}.
FT   STRAND      303    305       {ECO:0000244|PDB:2L0S}.
FT   TURN        311    313       {ECO:0000244|PDB:1KI0}.
FT   HELIX       315    317       {ECO:0000244|PDB:1KI0}.
FT   STRAND      334    339       {ECO:0000244|PDB:1KI0}.
FT   STRAND      343    346       {ECO:0000244|PDB:1KI0}.
FT   STRAND      377    379       {ECO:0000244|PDB:4DUR}.
FT   STRAND      382    384       {ECO:0000244|PDB:4DUR}.
FT   STRAND      405    407       {ECO:0000244|PDB:1PK4}.
FT   TURN        413    415       {ECO:0000244|PDB:1KRN}.
FT   TURN        417    419       {ECO:0000244|PDB:2PK4}.
FT   STRAND      429    431       {ECO:0000244|PDB:1PMK}.
FT   STRAND      436    441       {ECO:0000244|PDB:1KRN}.
FT   STRAND      446    450       {ECO:0000244|PDB:1KRN}.
FT   STRAND      460    462       {ECO:0000244|PDB:4DUR}.
FT   STRAND      481    483       {ECO:0000244|PDB:2KNF}.
FT   STRAND      487    489       {ECO:0000244|PDB:4DUR}.
FT   STRAND      509    511       {ECO:0000244|PDB:5HPG}.
FT   STRAND      514    516       {ECO:0000244|PDB:5HPG}.
FT   TURN        518    520       {ECO:0000244|PDB:5HPG}.
FT   TURN        522    525       {ECO:0000244|PDB:4DUR}.
FT   STRAND      542    546       {ECO:0000244|PDB:5HPG}.
FT   STRAND      552    554       {ECO:0000244|PDB:5HPG}.
FT   STRAND      582    586       {ECO:0000244|PDB:1BUI}.
FT   STRAND      595    599       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      605    613       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      616    619       {ECO:0000244|PDB:1DDJ}.
FT   HELIX       621    624       {ECO:0000244|PDB:1DDJ}.
FT   HELIX       630    632       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      634    638       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      640    644       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      650    659       {ECO:0000244|PDB:1DDJ}.
FT   TURN        661    663       {ECO:0000244|PDB:1QRZ}.
FT   STRAND      667    673       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      698    703       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      708    710       {ECO:0000244|PDB:1DDJ}.
FT   TURN        711    714       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      717    724       {ECO:0000244|PDB:1DDJ}.
FT   HELIX       726    729       {ECO:0000244|PDB:1DDJ}.
FT   TURN        732    737       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      743    747       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      749    751       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      752    754       {ECO:0000244|PDB:1BML}.
FT   STRAND      763    767       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      769    778       {ECO:0000244|PDB:1DDJ}.
FT   HELIX       780    782       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      791    795       {ECO:0000244|PDB:1DDJ}.
FT   HELIX       796    798       {ECO:0000244|PDB:1DDJ}.
FT   HELIX       800    808       {ECO:0000244|PDB:1DDJ}.
SQ   SEQUENCE   810 AA;  90569 MW;  8B31CB877CCB3AB6 CRC64;
     MEHKEVVLLL LLFLKSGQGE PLDDYVNTQG ASLFSVTKKQ LGAGSIEECA AKCEEDEEFT
     CRAFQYHSKE QQCVIMAENR KSSIIIRMRD VVLFEKKVYL SECKTGNGKN YRGTMSKTKN
     GITCQKWSST SPHRPRFSPA THPSEGLEEN YCRNPDNDPQ GPWCYTTDPE KRYDYCDILE
     CEEECMHCSG ENYDGKISKT MSGLECQAWD SQSPHAHGYI PSKFPNKNLK KNYCRNPDRE
     LRPWCFTTDP NKRWELCDIP RCTTPPPSSG PTYQCLKGTG ENYRGNVAVT VSGHTCQHWS
     AQTPHTHNRT PENFPCKNLD ENYCRNPDGK RAPWCHTTNS QVRWEYCKIP SCDSSPVSTE
     QLAPTAPPEL TPVVQDCYHG DGQSYRGTSS TTTTGKKCQS WSSMTPHRHQ KTPENYPNAG
     LTMNYCRNPD ADKGPWCFTT DPSVRWEYCN LKKCSGTEAS VVAPPPVVLL PDVETPSEED
     CMFGNGKGYR GKRATTVTGT PCQDWAAQEP HRHSIFTPET NPRAGLEKNY CRNPDGDVGG
     PWCYTTNPRK LYDYCDVPQC AAPSFDCGKP QVEPKKCPGR VVGGCVAHPH SWPWQVSLRT
     RFGMHFCGGT LISPEWVLTA AHCLEKSPRP SSYKVILGAH QEVNLEPHVQ EIEVSRLFLE
     PTRKDIALLK LSSPAVITDK VIPACLPSPN YVVADRTECF ITGWGETQGT FGAGLLKEAQ
     LPVIENKVCN RYEFLNGRVQ STELCAGHLA GGTDSCQGDS GGPLVCFEKD KYILQGVTSW
     GLGCARPNKP GVYVRVSRFV TWIEGVMRNN
//
